- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
KRX Growth Companies With High Insider Ownership
Reviewed by Simply Wall St
The South Korean stock market recently experienced a significant downturn, with the KOSPI index dropping sharply amid global concerns of an economic slowdown in the United States. Despite this volatility, growth companies with high insider ownership can offer unique investment opportunities due to their potential for strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.5% | 35% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.1% | 36.4% |
Bioneer (KOSDAQ:A064550) | 17.5% | 89.7% |
Global Tax Free (KOSDAQ:A204620) | 18.1% | 72.4% |
Seojin SystemLtd (KOSDAQ:A178320) | 29.6% | 58.7% |
Vuno (KOSDAQ:A338220) | 19.5% | 105% |
UTI (KOSDAQ:A179900) | 33.1% | 122.7% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 77.4% |
HANA Micron (KOSDAQ:A067310) | 20% | 97.4% |
Techwing (KOSDAQ:A089030) | 18.7% | 77.8% |
Here's a peek at a few of the choices from the screener.
Daejoo Electronic Materials (KOSDAQ:A078600)
Simply Wall St Growth Rating: ★★★★★★
Overview: Daejoo Electronic Materials Co., Ltd. develops and sells electronic materials across various regions including South Korea, China, Taiwan, the United States, Europe, and Southeast Asia with a market cap of ₩1.65 trillion.
Operations: The company generates revenue of ₩193.79 billion from the development, production, and sale of electrical and electronic components.
Insider Ownership: 28.9%
Earnings Growth Forecast: 55.8% p.a.
Daejoo Electronic Materials, a growth company with high insider ownership in South Korea, is forecast to see significant earnings growth of 55.8% annually over the next three years, outpacing the market. Despite recent volatility and interest payments not being well covered by earnings, the company became profitable this year. Recent private placements totaling KRW 61 billion reflect strong investor confidence and are expected to support its robust revenue growth forecast of 39% per year.
- Unlock comprehensive insights into our analysis of Daejoo Electronic Materials stock in this growth report.
- Our comprehensive valuation report raises the possibility that Daejoo Electronic Materials is priced higher than what may be justified by its financials.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc., a bio company with a market cap of ₩15.67 billion, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Operations: The company's revenue segments primarily include long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Insider Ownership: 26.6%
Earnings Growth Forecast: 72.9% p.a.
ALTEOGEN Inc. is poised for significant growth, with earnings projected to increase by 72.95% annually over the next three years, outpacing the South Korean market's growth rate. Recent MFDS approval of Tergase® marks a pivotal milestone, enhancing its product portfolio and commercial prospects. Despite high share price volatility and past shareholder dilution, ALTEOGEN trades at a substantial discount to its estimated fair value and boasts high return on equity forecasts (45.2%).
- Click here to discover the nuances of ALTEOGEN with our detailed analytical future growth report.
- Our valuation report here indicates ALTEOGEN may be overvalued.
Enchem (KOSDAQ:A348370)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enchem Co., Ltd. manufactures and sells electrolytes and additives for secondary batteries and EDLC, with a market cap of ₩3.65 trillion.
Operations: Enchem's revenue from electronic components and parts amounts to ₩357.37 billion.
Insider Ownership: 19.4%
Earnings Growth Forecast: 144.8% p.a.
Enchem is forecast to achieve significant revenue growth of 56.5% annually, well above the South Korean market average. The company is expected to become profitable within three years, reflecting strong earnings potential with an annual growth rate of 144.8%. Despite recent share price volatility and past shareholder dilution, high insider ownership aligns management interests with shareholders, suggesting confidence in Enchem's future performance and strategic direction.
- Get an in-depth perspective on Enchem's performance by reading our analyst estimates report here.
- The valuation report we've compiled suggests that Enchem's current price could be inflated.
Key Takeaways
- Get an in-depth perspective on all 84 Fast Growing KRX Companies With High Insider Ownership by using our screener here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Exceptional growth potential with excellent balance sheet.